Bristol Myers Squibb Company (NYSE:BMY) Stock Rated "Hold" by Wall Street Brokerages

Key Points

• Bristol Myers Squibb has a consensus “Hold” rating from 30 analysts, with a 12-month average price target of $65.46; 13 analysts rate it Buy or Strong Buy and 17 rate it Hold or Sell.
• The company beat quarterly earnings and revenue expectations, reporting adjusted EPS of $1.35 and revenue of $13.07 billion; revenue rose 6.9% year over year.
• Shares recently traded at $63.39, and the company’s $2.52 annualized dividend represents a yield of about 4.0%.

Shares of Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) have been assigned a consensus rating of "Hold" from the thirty research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, sixteen have issued a hold recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $65.46.

BMY has been the subject of several recent analyst reports. TD Cowen assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating for the company. Piper Sandler dropped their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an "overweight" rating for the company in a research report on Monday, October 26th. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Cantor Fitzgerald cut their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating on the stock in a report on Thursday, October 8th. Finally, UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th.

Insiders Place Their Bets

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by corporate insiders.

Institutional Trading of Bristol Myers Squibb

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Freedom LLC purchased a new stake in Bristol Myers Squibb in the 3rd quarter worth $26,000. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $27,000. Addison Advisors LLC purchased a new stake in Bristol Myers Squibb in the second quarter valued at $32,000. Groupe la Francaise raised its stake in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 501 shares during the last quarter. Finally, Arlington Trust Co LLC acquired a new position in Bristol Myers Squibb during the second quarter worth $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

More Bristol Myers Squibb News

Investors following BMY have been watching these news items:

• Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
• Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
• Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Bristol Myers Squibb Price Performance

Shares of NYSE BMY traded up $1.07 during mid-day trading on Friday, reaching $63.39. The company had a trading volume of 9,273,842 shares, compared to its average volume of 10,342,026. The firm has a market cap of $129.57 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb has a one year low of $45.26 and a one year high of $68.64. The business's 50-day simple moving average is $61.90 and its 200 day simple moving average is $60.31.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same period last year, the firm posted $1.63 earnings per share. The business's revenue for the quarter was up 6.9% on a year-over-year basis. On average, research analysts predict that Bristol Myers Squibb will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.88%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.